EP1140171A4 - Techniques et produits permettant de reguler l'activation du complement associee a la voie du complement a lectine - Google Patents

Techniques et produits permettant de reguler l'activation du complement associee a la voie du complement a lectine

Info

Publication number
EP1140171A4
EP1140171A4 EP99967362A EP99967362A EP1140171A4 EP 1140171 A4 EP1140171 A4 EP 1140171A4 EP 99967362 A EP99967362 A EP 99967362A EP 99967362 A EP99967362 A EP 99967362A EP 1140171 A4 EP1140171 A4 EP 1140171A4
Authority
EP
European Patent Office
Prior art keywords
products
methods
pathway associated
complement
regulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99967362A
Other languages
German (de)
English (en)
Other versions
EP1140171A1 (fr
Inventor
Gregory L Stahl
Charles D Collard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of EP1140171A1 publication Critical patent/EP1140171A1/fr
Publication of EP1140171A4 publication Critical patent/EP1140171A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP99967362A 1998-12-15 1999-12-15 Techniques et produits permettant de reguler l'activation du complement associee a la voie du complement a lectine Withdrawn EP1140171A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11239098P 1998-12-15 1998-12-15
PCT/US1999/029919 WO2000035483A1 (fr) 1998-12-15 1999-12-15 Techniques et produits permettant de reguler l'activation du complement associee a la voie du complement a lectine
US112390P 2008-11-07

Publications (2)

Publication Number Publication Date
EP1140171A1 EP1140171A1 (fr) 2001-10-10
EP1140171A4 true EP1140171A4 (fr) 2002-03-13

Family

ID=22343639

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99967362A Withdrawn EP1140171A4 (fr) 1998-12-15 1999-12-15 Techniques et produits permettant de reguler l'activation du complement associee a la voie du complement a lectine

Country Status (4)

Country Link
EP (1) EP1140171A4 (fr)
JP (1) JP2002532079A (fr)
CA (1) CA2347734A1 (fr)
WO (1) WO2000035483A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US7273925B1 (en) 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
JP2003507338A (ja) * 1999-08-13 2003-02-25 ザ ブリグハム アンド ウイメンズ ホスピタル インコーポレイテッド レクチン補体経路（ｌｃｐ）のインヒビターおよびその使用
WO2002006460A2 (fr) * 2000-07-13 2002-01-24 Jens Christian Jensenius Masp-2, enzyme de fixation de complements et ses utilisations
EP1186299A1 (fr) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht Diagnostic, prévention et/ou traitement d' athérosclérose, infections et perturbations du système immunitaire
EP1601377A4 (fr) 2003-02-21 2009-07-15 Genentech Inc Procedes de traitement et de prevention des lesions tissulaires associees aux blessures par reperfusion ischemique
EP2374819B1 (fr) 2003-05-12 2017-03-22 Helion Biotech ApS Anticorps contre MASP-2
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2007095154A2 (fr) 2006-02-10 2007-08-23 The Brigham And Women's Hospital, Inc. Dosages de la voie du complement de la lectine et compositions et procedes associes
PT3028716T (pt) 2006-10-10 2020-11-23 Regenesance B V Inibição do complemento para regeneração nervosa melhorada
ES2617920T3 (es) 2009-10-16 2017-06-20 Omeros Corporation Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
AU2011268110B2 (en) 2010-06-19 2016-05-19 Memorial Sloan-Kettering Cancer Center Anti-GD2 antibodies
DK2694108T3 (en) 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
KR101641057B1 (ko) 2011-05-04 2016-07-20 오메로스 코포레이션 Masp-2 의존적 보체 활성화를 억제하는 조성물
CN105705165B (zh) 2013-03-15 2020-04-24 纪念斯隆-凯特琳癌症中心 高亲和力抗gd2抗体
CN108588033B (zh) * 2018-04-24 2021-09-24 富恩生物技术（成都）有限公司 杂交瘤细胞株、cd31单克隆抗体、制备方法及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001519A1 (fr) * 1987-08-20 1989-02-23 Children's Hospital Corporation Proteine humaine liant le mannose
WO1991006010A1 (fr) * 1989-10-11 1991-05-02 Institute Of Child Health Procedure de diagnostic
JPH06121695A (ja) * 1992-10-13 1994-05-06 Fuji Yakuhin Kogyo Kk 抗ヒトマンノース結合蛋白モノクローナル抗体およびその利用
JPH07238100A (ja) * 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd ヒトのｍａｓｐに対するモノクローナル抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
DE3927723A1 (de) * 1989-01-26 1990-08-02 Ulrich Prof Dr Speck N - acetylglucosamin zur buccalen anwendung
AU3881493A (en) * 1992-03-19 1993-10-21 University Of British Columbia, The Method and composition for suppression of side effects of anti-inflammatory drugs
US5998173A (en) * 1996-02-20 1999-12-07 The University Of Bristish Columbia Process for producing N-acetyl-D-glucosamine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001519A1 (fr) * 1987-08-20 1989-02-23 Children's Hospital Corporation Proteine humaine liant le mannose
WO1991006010A1 (fr) * 1989-10-11 1991-05-02 Institute Of Child Health Procedure de diagnostic
JPH06121695A (ja) * 1992-10-13 1994-05-06 Fuji Yakuhin Kogyo Kk 抗ヒトマンノース結合蛋白モノクローナル抗体およびその利用
JPH07238100A (ja) * 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd ヒトのｍａｓｐに対するモノクローナル抗体

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CHAKA W ET AL: "Induction of TNF-alpha in human peripheral blood mononuclear cells by the mannoprotein of cryptococcus neoformans involves human mannose binding protein", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 159, 1997, pages 2979 - 2985, XP002145899, ISSN: 0022-1767 *
COLLARD C D ET AL: "ENDOTHELIAL REOXYGENATION ACTIVATES THE LECTIN COMPLEMENT PATHWAY: INHIBITION WITH ANTI-HUMAN MANNOSE BINDING LECTIN(MBL) THERAPY", MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 36, no. 4/5, March 1999 (1999-03-01), pages 278, XP000944464, ISSN: 0026-895X *
COLLARD C D ET AL: "REOXYGENATION OF HYPOXIC HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS (HUVECS) ACTIVATES THE LECTIN COMPLEMENT PATHWAY (LCP)", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 12, no. 4, 17 March 1998 (1998-03-17), pages A29, XP000944437, ISSN: 0892-6638 *
ENDO M ET AL: "GLOMERULA DEPOSITION OF MANNOSE-BINDING LECTIN (MBL) INDICATES A NOVEL MECHANISM OF COMPLEMENT ACTIVATION IN IGA NEPHROPATHY", NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIVERSITY PRESS, GB, vol. 13, no. 8, 1998, pages 1984 - 1990, XP000874166, ISSN: 0931-0509 *
LHOTTA K ET AL: "GLOMERULAR DEPOSITION OF MANNOSE-BINDING LECTIN IN HUMAN GLOMERULONEPHRITIS", NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIVERSITY PRESS, GB, vol. 14, no. 4, April 1999 (1999-04-01), pages 881 - 886, XP000944395, ISSN: 0931-0509 *
PATENT ABSTRACTS OF JAPAN vol. 018, no. 410 (C - 1232) 2 August 1994 (1994-08-02) *
PATENT ABSTRACTS OF JAPAN vol. 1996, no. 01 31 January 1996 (1996-01-31) *
See also references of WO0035483A1 *
TENNER A J ET AL: "MANNOSE BINDING PROTEIN (MBP) ENHANCES MONONUCLEAR PHAGOCYTE FUNCTION VIA A RECEPTOR THAT CONTAINS THE 126,00 MR COMPONENT OF THE C1Q RECEPTOR", IMMUNITY, CELL PRESS, US, vol. 3, no. 4, 1 October 1995 (1995-10-01), pages 485 - 493, XP002058774, ISSN: 1074-7613 *
TERAI I ET AL: "ALPHA2-MACROGLOBULIN BINDS TO AND INHIBITS MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASE", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 7, no. 10, October 1995 (1995-10-01), pages 1579 - 1584, XP001034131, ISSN: 0953-8178 *

Also Published As

Publication number Publication date
JP2002532079A (ja) 2002-10-02
EP1140171A1 (fr) 2001-10-10
WO2000035483A1 (fr) 2000-06-22
CA2347734A1 (fr) 2000-06-22

Similar Documents

Publication Publication Date Title
EP1140171A4 (fr) Techniques et produits permettant de reguler l'activation du complement associee a la voie du complement a lectine
IL137963A0 (en) Compositions and methods for regulating lymphocyte activation
GB2348808B (en) Methods and compositions for desensitisation
GB2352005B (en) Hinge and method
HU9900636D0 (en) Confectionery product and process
EP1054603A4 (fr) Produits du tabac a la vitamine e
GB9808461D0 (en) Solid borate-diol interaction products
GB9715293D0 (en) Monitor and/or overload means
IL138207A0 (en) Methods and devices for modulating the immune response
LU90658B1 (en) Process for de-chlorinating and de-fouling oil
GB9615405D0 (en) Chocolate products
PL332631A1 (en) Spray-crystallised products and associated methods
IL120554A0 (en) Kombucha products and processes for the preparation thereof
AU2752399A (en) Method for continuous casting and device for carrying out the method
HK1036273A1 (en) Pyridine derivative and pharmaceutical containing the same
PL343432A1 (en) Methods and devices for modulating the immune response
GB9717104D0 (en) Food products
AU7764798A (en) Product and method for providing glutamine
AU6010998A (en) Method and device for the continuous cooking of pulp
GB9826121D0 (en) Products and methods
TW306166U (en) Rootstalk product slicer and shredder
GB9825926D0 (en) Refractory products and their manufacture
GB9825250D0 (en) Products and processes therefor
GB0221730D0 (en) Food products
ZA98760B (en) Antimicrobial composition and method for food products

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010613

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020124

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 39/395 A, 7C 12N 5/06 B, 7C 12N 5/16 B, 7G 01N 33/50 B

17Q First examination report despatched

Effective date: 20020912

17Q First examination report despatched

Effective date: 20020912

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080529